Wyoming Medicaid GLP-1 Coverage 2026: Pattern #47 — Categorical Anorexiant Exclusion Under WDH/DHCF Pharmacy Services Manual Rev 27 With Active FDA-Label Carve-Ins (Wegovy SELECT + Wegovy MASH + Zepbound OSA) Inside the Smallest US State Medicaid Program During an April 15, 2026 OptumRx Pharmacy-Benefit Migration

TL;DR — what Wyoming Medicaid covers and does not cover

The categorical exclusion anchor is verbatim on the WY Medicaid Pharmacy Services Manual Revision 27 (effective April 15, 2026), page 8, Section “Legend Drug Exclusions (All Medicaid Plans)”:

“LEGEND DRUG EXCLUSIONS (ALL MEDICAID PLANS) • Anorexiant products • Androgenic or anabolic steroids used for weight gain • Agents used to promote fertility • Acne agents for clients who are not 12 to 20 years of age • Erectile dysfunction medications • DESI, as well as similar, related or identical drugs considered to be less effective by the Food and Drug Administration (FDA) • Compound prescriptions, which include a DESI drug, will deny…”

What WY Medicaid does NOT cover (categorical anorexiant exclusion):

• Wegovy (semaglutide) for chronic weight management
• Zepbound (tirzepatide) for chronic weight management
• Saxenda (liraglutide) for chronic weight management (absent from PDL)
• Contrave (naltrexone/bupropion) for chronic weight management — UNVERIFIED whether the branded fixed-combination Contrave is excluded under the “Anorexiant products” bucket; component coverage is UNVERIFIED
• Qsymia (phentermine/topiramate) for chronic weight management — UNVERIFIED
• Phentermine, phendimetrazine, diethylpropion (Schedule IV anorexiants) for chronic weight management — UNVERIFIED component coverage

What WY Medicaid DOES cover via FDA-label-restricted carve-ins (PA required):

What WY Medicaid covers for T2D (PDL April 15, 2026, Incretin Mimetics / GLP-1 Receptor Agonists section):

• Preferred: exenatide, RYBELSUS, TRULICITY, VICTOZA (brand is preferred)
• Non-preferred (PA required): liraglutide (use brand), MOUNJARO, OZEMPIC (brand is preferred), SOLIQUA, XULTOPHY

Clinical criteria verbatim from the WY Medicaid PDL Incretin Mimetics section:

“Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent unless ASCVD or risk factors are present, in which case the trial of metformin is waived. A 90 day trial of failure of the preferred agent is required before approval can be given for a non-preferred agent. Dosage Limits Apply: Ozempic: 2mg/week; Victoza: 1.8mg/day.”

Notable T2D formulary quirks:

• Brand Victoza preferred / generic liraglutide non-preferred — the inverse of the usual generics-preferred pharmacy-benefit pattern; same rebate-driven pattern seen in ND Pattern #44.
• Ozempic non-preferred AND brand-preferred — meaning if a patient is approved for Ozempic through the non-preferred-agent PA pathway, the brand Ozempic pen is dispensed (UNVERIFIED whether an authorized generic semaglutide is available in the WY market).
• ASCVD waiver of the metformin trial — clinically aligned with ADA Standards of Care 2026 recommendations to use GLP-1 receptor agonists with proven cardiovascular benefit first-line in T2D + ASCVD or ASCVD risk factors.

Architectural distinctive features:

• Smallest US state Medicaid program by enrollment — ~59,714 covered (CMS October 2025); state population ~580,000 (smallest US state by population). KFF May 2025 cites a higher ~71,000 (UNVERIFIED variance).
• Non-expansion state — one of 10 remaining; 2026 session budget amendments to add Medicaid expansion DEFEATED 7-23 (February 19) and 5-26 (February 22, 2026).
• Categorical “Anorexiant products” exclusion — explicit verbatim in the WDH Pharmacy Services Manual Revision 27 page 8 Legend Drug Exclusions bucket.
• Three concretely-codified FDA-label carve-ins — Wegovy CV (SELECT) + Wegovy MASH + Zepbound OSA all active on the April 15, 2026 PDL.
• FFS-only architecture — no traditional Medicaid MCO; OptumRx as sole pharmacy benefit administrator. Single PA decision-maker, single fax (1-866-964-3472). WYhealth as Care Management Entity (CME), not capitated MCO.
• Energy-economy fiscal posture — Real Chemistry projected Wyoming’s marginal cost of adding GLP-1 obesity coverage at “less than $5 million annually” against a state surplus driven by oil/gas extraction taxes. Despite the fiscal capacity, no AOM legislation has been introduced.
• Sparsest US geography — 580K population, 97,914 square miles, lowest population density of any US state. Endocrinology / hepatology / cardiology / sleep-medicine subspecialty access outside Cheyenne, Casper, Laramie, Gillette, and Jackson is thin.
• Pharmacy benefit migration mid-2026 — all pharmacy claims and prior authorizations migrated to OptumRx systems on April 15, 2026.
• State-employee plan inverse-coverage posture — Wyoming Employees’ Group Insurance (EGI) launched a new GLP-1 weight management program through CVS Caremark effective January 1, 2026 covering AOM GLP-1s — state-employee coverage is more generous than Medicaid coverage for the obesity indication. Same inverse-coverage posture seen in ND Pattern #44 (commercial EHB Benchmark) and a recurring pattern across categorical exclusion states.

Pharmacy benefit architecture:

• Pharmacy benefit administrator: OptumRx (effective April 15, 2026)
• OptumRx WY Pharmacy Help Desk: 1-877-209-1264
• OptumRx WY PA/Appeals/Clinical Call Center: 1-877-207-1126
• OptumRx PA Department: PO Box 21719, Cheyenne, WY 82003
• OptumRx PA fax: 1-866-964-3472
• WDH Customer Service Center: 1-855-294-2127 (TTY 1-855-329-5204)
• WDH/DHCF main number: (307) 777-7531
• WDH/DHCF address: 122 W 25th St., 4th Floor West, Cheyenne, WY 82001
• Care management entity: WYhealth (NOT a capitated MCO)

1. The categorical anorexiant exclusion — verbatim primary source

The Wyoming Medicaid Pharmacy Services Manual, Revision 27, effective April 15, 2026, page 8, Section “Legend Drug Exclusions (All Medicaid Plans)” reads verbatim:

“LEGEND DRUG EXCLUSIONS (ALL MEDICAID PLANS)

• Anorexiant products

• Androgenic or anabolic steroids used for weight gain

• Agents used to promote fertility

• Acne agents for clients who are not 12 to 20 years of age

• Erectile dysfunction medications

• DESI, as well as similar, related or identical drugs considered to be less effective by the Food and Drug Administration (FDA)

• Compound prescriptions, which include a DESI drug, will deny…”

This is the categorical exclusion that gates Wegovy (when prescribed for the chronic-weight-management indication), Zepbound (when prescribed for the chronic-weight-management indication), Saxenda, Contrave, and Qsymia. Saxenda is absent from the WY Medicaid PDL entirely.

The phrase “Anorexiant products” is the same regulatory term used in CMS Manual System (Pub. 100-04 Medicare Claims Processing) and in the federal Social Security Act § 1927(d)(2)(A), which permits state Medicaid programs to exclude “agents when used for anorexia, weight loss, or weight gain.” The federal authority to categorically exclude AOM coverage from Medicaid is unambiguous; the policy choice belongs to each state.

Real Chemistry’s December 2024 analysis “State-by-state analysis of Medicaid coverage for GLP-1 weight loss” named Wyoming together with North Dakota as the two lowest-spending states in this category: “The states with the lowest spending, North Dakota and Wyoming, don’t provide Medicaid coverage for any of the obesity-indicated GLP-1s.” Wyoming is NOT in the KFF January 2026 13-state cohort of states actively covering GLP-1s for obesity.

2. Wegovy cardiovascular carve-in — verbatim FDA SELECT adoption

The WY Medicaid Additional Therapeutic Criteria Chart (effective April 15, 2026), Wegovy line, reads verbatim:

“WEGOVY. Client must have BMI of 27 or higher with cardiovascular disease defined as prior myocardial infarction, prior stroke, or peripheral artery disease.”

This is a verbatim adoption of the FDA Wegovy SELECT cardiovascular-risk-reduction label. The FDA approved Wegovy’s SELECT supplement on March 8, 2024, for the indication of reducing the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight (BMI ≥ 27 kg/m²).

Required clinical documentation for the Wegovy CV PA:

• BMI: documented BMI ≥ 27 kg/m².
• Cardiovascular disease (one of the three required categories):
  • Prior myocardial infarction — ICD-10 I21.x (acute MI), I25.2 (old MI)
  • Prior stroke — ICD-10 I63.x (cerebral infarction), I69.x (sequelae of cerebrovascular disease)
  • Peripheral artery disease — ICD-10 I70.2x (atherosclerosis of native arteries of extremities), I73.9 (peripheral vascular disease, unspecified)
• Provider type: cardiology, vascular medicine, or neurology consultation is not specified in the ATC chart as a prerequisite (UNVERIFIED whether OptumRx requires it operationally on PA review).
• T2D status: the ATC chart does NOT require T2D-negative status (unlike ND Pattern #44, which requires A1c-normal-off-Rx documentation). Wyoming patients with both T2D and SELECT-eligible cardiovascular disease can qualify for Wegovy CV — though most such patients should be considered for T2D-indicated Ozempic 2.0 mg first under the T2D PDL pathway.

Notable comparison to ND Pattern #44: ND requires an off-label step-through to diabetes-indicated Ozempic 2 mg BEFORE Wegovy is authorized for SELECT/MACE (even though Ozempic itself is not FDA-labeled for MACE without T2D). WY does NOT impose this step-through. WY’s Wegovy CV criteria are materially less restrictive than ND’s.

PA submission: No dedicated AOM PA form exists in Wyoming. For the Wegovy CV indication, use the Miscellaneous PA Form or the Brand Name PA Form from the WY Medicaid PA forms hub (https://www.wymedicaid.org/pa-pdl/pa-forms-related-info.html). Submit by fax to OptumRx PA Department at 1-866-964-3472.

Approval duration: UNVERIFIED in publicly available WY Medicaid documentation. The federal floor under 42 CFR § 440.230 is medical-necessity-based reauthorization; the practical expectation is a 6-12 month initial approval.

3. Wegovy MASH carve-in — PDL line with ATC inconsistency

The WY Medicaid PDL (effective April 15, 2026), MASH (Metabolic-Associated Steatohepatitis) section page 8, reads verbatim:

“APPROVED AGENTS: WEGOVY (INJECTABLE)* *Wegovy injectables will require diagnosis of MASH. Please consult the Additional Therapeutics Clinical Criteria chart for more information regarding cardiovascular disease criteria.”

Verbatim PDL/ATC inconsistency flagged UNVERIFIED: the PDL line declares Wegovy MASH-approved with a footnote redirecting to the Additional Therapeutic Criteria Chart “for more information regarding cardiovascular disease criteria” — but the ATC chart itself only lists the cardiovascular-disease criterion (BMI ≥ 27 + prior MI/stroke/PAD), with no MASH-specific criteria language published. This means the operational MASH PA review criteria are not publicly documented as of the April 15, 2026 effective date.

Required clinical documentation for the Wegovy MASH PA (practical expectation based on sister-state pattern):

• ICD-10 diagnosis: K75.81 (nonalcoholic steatohepatitis) — the standard MASH diagnosis code.
• Fibrosis stage documentation: F2 or F3 fibrosis by biopsy, vibration-controlled transient elastography (VCTE) / FibroScan, MR-PDFF (proton density fat fraction), MR elastography (MRE), or Enhanced Liver Fibrosis (ELF) score. The FDA Wegovy MASH supplement label expansion in August 2025 was based on the ESSENCE trial of MASH with F2/F3 fibrosis — the practical PA expectation aligns with the trial population.
• Provider type: hepatology, gastroenterology, or endocrinology consultation is the practical expectation.
• Alcohol-abstinence biomarker: the WY Medicaid PDL does not specify a PEth (phosphatidylethanol) threshold (unlike ND Pattern #44, which requires PEth < 20 ng/mL with 5-year alcohol-use history). Practical PA preparation should still document alcohol-use history and abstinence.

Approval duration: UNVERIFIED. The practical expectation is 6-12 month initial approval with fibrosis-stage stabilization or improvement at reauthorization.

Wyoming’s Wegovy MASH coverage is implemented in the wake of the FDA’s August 2025 semaglutide MASH-specific label expansion (Novo Nordisk supplemental NDA approval). Patients with both MASH and SELECT-eligible cardiovascular disease may qualify under either pathway; the CV criterion is the more concretely codified of the two.

4. Zepbound OSA carve-in — AHI > 15 with 5% weight-loss reauthorization

The WY Medicaid PDL (effective April 15, 2026), Obstructive Sleep Apnea section page 9, reads verbatim:

“OBSTRUCTIVE SLEEP APNEA. GLP-1 Agonists: ZEPBOUND. Client must have diagnosis of moderate to severe obstructive sleep apnea. Will be approved for obese adults with an AHI (Apnea-Hypopnea Index) of greater than 15 as evidenced by sleep study within the prior 12 months. Prior authorization will be required again at 6 months to show at least 5% weight loss. Prior authorization will be required again at 12 months to demonstrate improvement in obstructive sleep apnea.”

Required clinical documentation for the Zepbound OSA PA:

• ICD-10 diagnosis: G47.33 (obstructive sleep apnea, adult).
• Sleep study: in-lab attended polysomnography (PSG) or home sleep apnea test (HSAT) within the prior 12 months showing AHI > 15. The PDL line does not specifically require in-lab attended PSG (UNVERIFIED) — HSAT may be acceptable.
• BMI: “obese adults” — the numeric BMI threshold is NOT specified in the PDL line. The most likely applicable threshold is the FDA Zepbound label baseline of BMI ≥ 30 kg/m² (UNVERIFIED in the PDL line).
• Prior CPAP requirement: NOT specified in the PDL line. Wyoming’s Zepbound OSA criteria are materially less restrictive than ND Pattern #44, which requires a 6-month CPAP failure prerequisite + a 6-month semaglutide-or-equivalent comprehensive weight-management program. Wyoming requires only the sleep study and BMI documentation.
• Provider type: not specified in the PDL line (UNVERIFIED whether sleep-medicine specialist prescribing or consultation is required operationally).

Reauthorization timeline (verbatim PDL):

• 6 months: reauthorization PA required to demonstrate ≥ 5% weight loss from baseline.
• 12 months: reauthorization PA required to demonstrate improvement in obstructive sleep apnea (specific metric — AHI decrease, OSA-severity-status change, Epworth Sleepiness Scale change — is NOT specified in the PDL line and is UNVERIFIED).

Comparison to ND Pattern #44 Zepbound OSA criteria:

• CPAP prerequisite: WY does NOT require CPAP failure; ND requires 6-month CPAP failure.
• Weight-management program prerequisite: WY does NOT require a comprehensive weight-management program; ND requires 6 months of comprehensive weight-management program with semaglutide.
• Weight-loss reauthorization threshold: WY requires 5% at 6 months; ND requires 10% at 12 months.
• Mounjaro-vs-Zepbound adjudication: WY does NOT impose the “most cost-effective tirzepatide product” clause; ND does.

Wyoming’s Zepbound OSA criteria are among the LEAST restrictive in the 50-state series for the OSA carve-in indication.

5. T2D GLP-1 receptor agonist pathway — preferred / non-preferred tiers + step-therapy

The WY Medicaid PDL (effective April 15, 2026), Incretin Mimetics / GLP-1 Receptor Agonists section, lists:

• Preferred (subject to step-therapy):
  • exenatide (Bydureon, Byetta)
  • RYBELSUS (oral semaglutide)
  • TRULICITY (dulaglutide)
  • VICTOZA (liraglutide — brand is preferred)
• Non-preferred (PA required):
  • liraglutide (use brand)
  • MOUNJARO (tirzepatide)
  • OZEMPIC (semaglutide — brand is preferred)
  • SOLIQUA (insulin glargine + lixisenatide)
  • XULTOPHY (insulin degludec + liraglutide)

Clinical criteria verbatim from the WY Medicaid PDL Incretin Mimetics section:

“Trial and failure of metformin greater than or equal to a 90 day supply in the last 12 months will be required before approval can be given for a preferred agent unless ASCVD or risk factors are present, in which case the trial of metformin is waived. A 90 day trial of failure of the preferred agent is required before approval can be given for a non-preferred agent.”

“Dosage Limits Apply: Ozempic: 2mg/week; Victoza: 1.8mg/day.”

Step-therapy implications:

• Standard T2D patient: metformin ≥ 90-day trial → preferred GLP-1 (exenatide, Rybelsus, Trulicity, or brand Victoza).
• T2D patient with ASCVD or ASCVD risk factors: metformin trial WAIVED → preferred GLP-1 first-line. Clinically aligned with ADA Standards of Care 2026 recommendations.
• T2D patient who failed a preferred GLP-1 ≥ 90 days: PA pathway to non-preferred agent (Ozempic, Mounjaro, generic liraglutide, Soliqua, or Xultophy).

Notable Pattern #47 quirks:

• Brand Victoza preferred, generic liraglutide non-preferred (“use brand”). The PDL explicitly directs “use brand” for liraglutide — the inverse of the usual generics-preferred pharmacy-benefit pattern. This is driven by Novo Nordisk supplemental rebate agreements with the WY Medicaid pharmacy program, not by acquisition-cost economics.
• Ozempic non-preferred AND brand-preferred. If a patient is approved for Ozempic through the non-preferred-agent PA pathway, the brand Ozempic pen is dispensed.
• Dosage cap on Ozempic at 2 mg/week and Victoza at 1.8 mg/day. Both caps are at the FDA-labeled maximum doses for the T2D indication. The cap on Ozempic at 2 mg/week mirrors the SUSTAIN-FORTE supplemental-NDA-approved 2.0 mg dose ceiling for T2D (the 2.4 mg dose is reserved for the Wegovy SELECT/CV indication, not the Ozempic T2D label).

6. PA submission pathway — OptumRx fax 1-866-964-3472

No dedicated AOM PA form exists in Wyoming (consistent with the categorical “Anorexiant products” exclusion). For the three covered carve-ins (Wegovy CV, Wegovy MASH, Zepbound OSA), the practical PA pathway is:

1. Confirm the indication is one of the covered carve-ins by reading the PDL effective April 15, 2026 (https://www.wymedicaid.org/content/dam/ffs-medicaid/wy/pdl-2026-041526.pdf) and the Additional Therapeutic Criteria Chart (https://www.wymedicaid.org/content/dam/ffs-medicaid/wy/atcc-41526.pdf).
2. Download the appropriate PA form from the WY Medicaid PA Forms hub: https://www.wymedicaid.org/pa-pdl/pa-forms-related-info.html. The most likely applicable forms are the Miscellaneous PA Form or the Brand Name PA Form.
3. Attach indication-specific clinical documentation:
   • For Wegovy CV: ICD-10 diagnosis code (I21.x / I25.2 / I63.x / I70.2x / I73.9) + BMI ≥ 27 + cardiology / vascular medicine / neurology consult note.
   • For Zepbound OSA: ICD-10 G47.33 + sleep study within prior 12 months showing AHI > 15 + BMI documentation.
   • For Wegovy MASH: ICD-10 K75.81 + biopsy or non-invasive-test fibrosis documentation (FibroScan, MR-PDFF, MRE, ELF score) + hepatology/GI/endocrinology consult note.
4. Submit by fax to the OptumRx PA Department at 1-866-964-3472. All WY Medicaid PA forms instruct verbatim: “Providers: Please submit completed PA forms to the Optum prior authorization team via fax at 1-866-964-3472.”
5. For status checks call the OptumRx PA/Appeals/Clinical Call Center at 1-877-207-1126.

Adjudication turnaround verbatim from the Pharmacy Services Manual page 22:

“If the request for the brand medication is approved, a prior authorization will be given within twenty-four (24) to seventy-two (72) [hours]…”

Approval durations:

• Wegovy CV: UNVERIFIED in publicly available WY documentation.
• Zepbound OSA: implied 6-month initial approval (PDL line: “Prior authorization will be required again at 6 months to show at least 5% weight loss”); 6-month continuation if 5% weight loss achieved; 12-month continuation contingent on documented OSA improvement.
• Wegovy MASH: UNVERIFIED.
• T2D preferred GLP-1s: standard 12-month PA cycle.
• T2D non-preferred GLP-1s: typically 6-12 month cycle depending on documentation.

7. Appeals architecture — reconsideration + Wyoming OAH administrative hearings

Wyoming Medicaid uses a two-step appeals architecture under Wyoming Medicaid Rules Chapter 4 (https://health.wyo.gov/wp-content/uploads/2024/04/WYDOH-Medicaid-Chapter-4.pdf). The statutory authority is Wyoming Statute § 42-4-101 et seq.

7.1 Step 1 — Reconsideration (20 business days from notice of denial)

Verbatim from the WY Medicaid Pharmacy Services Manual Revision 27 page 22:

“clients or the prescriber may request reconsideration of the decision to deny the request for prior authorization within twenty (20) business days of the receipt of the notice of denial.”

Submission method: Submit reconsideration request to OptumRx PA Department, PO Box 21719, Cheyenne, WY 82003 | Fax 1-866-964-3472.

Practical tactic: Many WY Medicaid PA denials are documentation deficiencies recoverable via reconsideration with strengthened clinical evidence. Call the OptumRx PA/Appeals/Clinical Call Center at 1-877-207-1126 to verify the denial rationale before drafting the reconsideration request.

7.2 Step 2 — Administrative hearing (20 business days from adverse-action notice)

Verbatim from Wyoming Medicaid Rules Chapter 4 §7:

“(a) A client’s request for a hearing shall be submitted electronically via email to the Department, made verbally to the Department, mailed to the Department via certified mail, return receipt requested, or personally delivered to the Department within twenty (20) business days after the mailing of the notice of adverse action.

(b) A provider’s request for a hearing shall be mailed via certified mail, return receipt requested, or personally delivered to the Department within twenty (20) business days after the mailing of the notice of adverse action.”

Verbatim §8(a):

“The Department shall evaluate the request and, within ten (10) business days following the receipt of the request notify the requesting party in writing whether the request has been accepted or rejected.”

Verbatim §11:

“A hearing shall be held within forty (40) days of the request for hearing unless otherwise provided by law, by agreement of the parties, or if a contestant requests a continuance.”

Hearing forum: Wyoming Office of Administrative Hearings (OAH), 1800 Carey Ave., 5th Floor, Cheyenne, WY 82002 | (307) 777-6660 | Fax (307) 777-5269.

7.3 Continuation of benefits during appeal — verbatim §9

“If the Department mails the required notice and the client requests a hearing before the effective date of the action, the Department may not terminate or reduce services until the final decision is rendered after the hearing…”

This is the federal-floor continuation-of-benefits guarantee under 42 CFR § 431.230 implemented at the Wyoming state level. For a previously-authorized GLP-1 PA being non-renewed (e.g., a Zepbound OSA reauthorization denied at the 6-month or 12-month mark), the patient should file the administrative hearing request BEFORE the effective date of the adverse action to preserve continuation of benefits during the appeal.

7.4 Expedited fair hearing

Federal 42 CFR § 431.224 applies. The default federal expedited timeline under § 431.244(f)(4) is 3 working days when the standard timeframe could jeopardize life, health, or function. WY-specific expedited fair-hearing deadline is UNVERIFIED in publicly available WDH documentation.

8. Wyoming Medicaid enrollment + architecture — smallest US state by population

Wyoming Medicaid is small even by sparsely-populated-state standards:

• 59,714 covered by Medicaid + CHIP per the CMS/Medicaid.gov October 2025 snapshot (via healthinsurance.org Wyoming Medicaid page).
• 71,000 (UNVERIFIED variance) per the KFF May 2025 Medicaid in Wyoming fact sheet — differing point-in-time and CHIP-inclusion assumptions are the likely driver of the variance.
• ~580,000 state population — Wyoming is the smallest US state by population.
• 97,914 square miles — the 10th-largest US state by area but the LEAST densely populated state at approximately 5.9 people per square mile.
• Non-expansion state — one of 10 remaining (alongside AL, FL, GA, KS, MS [partially adopted via SPA carve-back-in], SC, TN, TX, WI, WY).

Architectural distinctive features:

• FFS-only. No traditional Medicaid MCO. Wyoming Medicaid does not contract with full-risk capitated managed care organizations for the categorical groups (children, parents, pregnant women, disabled adults, seniors). Pharmacy claims and PAs are processed in fee-for-service.
• WYhealth as Care Management Entity (CME). Care management is performed by WYhealth, NOT a capitated MCO. WYhealth functions as a utilization management vendor under contract with WDH/DHCF.
• OptumRx as pharmacy benefit administrator. Effective April 15, 2026, all WY Medicaid pharmacy claims and PAs are processed in OptumRx systems. The historical timeline: Xerox held the contract before transferring to Optum in 2016; the migration to combined OptumRx systems occurred on April 15, 2026.
• Sparse geography. Endocrinology / hepatology / cardiology / sleep-medicine subspecialty access outside Cheyenne, Casper, Laramie, Gillette, and Jackson is thin. PA-clinical-consultation requirements that work in a dense state may be operationally burdensome in rural Wyoming.

9. 2026 legislative context — no AOM bills + Medicaid expansion defeated twice

There were NO Wyoming bills in the 2024-2025 or 2026 sessions specifically addressing GLP-1 or AOM Medicaid coverage.

The 2026 session Medicaid bills (none on AOM) included:

• SF0006 — codifies Medicaid eligibility and adopts federal Medicaid work requirements (80 hours/month).
• SF0004 — increases Medicaid reimbursement for EMS to 100% (approximately $1.3M fiscal note).
• HB0063 — would have increased skilled nursing facility (SNF) reimbursement by 5%. KILLED upon introduction.
• HB0064 — would have permitted WDH to apply for an enhanced Medicaid federal match for maternal services. KILLED upon introduction.
• HB0122 — Rural Health Transformation Program. Engrossed.

Medicaid expansion in Wyoming:

• Sen. Cale Case (R-Lander) offered budget amendments to add Medicaid expansion in the 2026 session.
• First vote (February 19, 2026): DEFEATED 7-23.
• Second vote (February 22, 2026): DEFEATED 5-26.
• Wyoming remains one of 10 non-expansion states.

Adjacent state-employee-plan context (NOT Medicaid): the Wyoming Employees’ Group Insurance (EGI) launched a new GLP-1 weight management program through CVS Caremark effective January 1, 2026 — expanded coverage beyond a prior 6-month lifetime cap. Source: https://ai.wyo.gov/divisions/human-resources/group-insurance/weight-management-glp1. The state-employee plan covers AOM GLP-1s; Medicaid does NOT.

This is the same inverse-coverage-posture pattern seen with North Dakota Pattern #44 (where the 2025 commercial EHB Benchmark Plan covers GLP-1s for morbid obesity but ND Medicaid does not) and is a recurring pattern in the categorical-exclusion states: state-employee plans negotiate AOM coverage through commercial PBM contracts (CVS Caremark in WY’s case) while Medicaid programs decline to add coverage under their state-plan pharmacy benefits.

10. Wyoming rural access friction — specialist density and tribal-health overlap

Wyoming’s sparse geography creates unique access friction for the GLP-1 carve-ins that require specialist consultation:

• Endocrinology density: Wyoming is among the lowest-density US states for endocrinologist practitioners per capita. Most endocrinology practices are concentrated in Cheyenne, Casper, and the larger regional centers (Laramie, Gillette, Jackson). Patients in rural counties may need to travel 100+ miles for specialist consultation.
• Hepatology density: similar friction for hepatology consultation required for Wegovy MASH PA preparation. Many Wyoming patients with MASH are managed by gastroenterology or primary care without dedicated hepatology consultation.
• Sleep medicine density: sleep-medicine specialists are concentrated in the larger regional centers. Home sleep apnea tests (HSATs) are operationally more accessible than in-lab attended polysomnography (PSG) for rural patients.
• Cardiology density: cardiology consultation for Wegovy CV PA preparation is available in regional referral centers; many rural patients are managed by primary care plus telemedicine cardiology consultations.

Tribal health overlap. Wyoming hosts the Wind River Indian Reservation (Eastern Shoshone and Northern Arapaho tribes). The Indian Health Service operates the Wind River Service Unit. AOM coverage through IHS and 638-tribally-operated facilities is UNVERIFIED in publicly available Wyoming Medicaid documentation — the categorical “Anorexiant products” exclusion presumptively applies to IHS-billed claims under the WY Medicaid plan, but operationalized carve-ins may differ from the published PDL language.

11. April 15, 2026 OptumRx pharmacy-benefit migration — operational continuity considerations

The OptumRx pharmacy-benefit migration is the load-bearing 2026 operational event for Wyoming Medicaid pharmacy benefits. Verbatim from wymedicaid.org:

“Effective April 15, 2026, all Wyoming Medicaid pharmacy claims and prior authorizations will be processed in new OptumRx systems.”

Operational continuity considerations for the migration:

• PA recertification. Open PAs in the pre-April-15 system may have been ported to the OptumRx system or may have required re-submission. Providers with active PAs (T2D non-preferred agents, Wegovy CV, Wegovy MASH, Zepbound OSA reauthorizations) should verify with OptumRx PA/Appeals/Clinical Call Center at 1-877-207-1126 whether their PAs are in good standing.
• New PA form versions. The April 15, 2026 PA forms hub (https://www.wymedicaid.org/pa-pdl/pa-forms-related-info.html) reflects the OptumRx system. Pre-migration forms may not be accepted.
• Claims processing. All pharmacy claims after April 15, 2026 are processed through OptumRx. The Pharmacy Help Desk at 1-877-209-1264 is the primary point of contact for claims-processing issues.
• Override line. Time-sensitive scenarios (e.g., a patient on the road in a Wyoming rural pharmacy needing an emergency T2D GLP-1 fill while a PA is pending) should be routed to the OptumRx PA/Appeals/Clinical Call Center at 1-877-207-1126 for clinical-judgment overrides.

11.5 Statutory framework — Wyoming Statute § 42-4-101 et seq.

The Wyoming Medicaid program is statutorily authorized under Wyoming Statute § 42-4-101 et seq. The relevant chapters and sections that gate AOM coverage and appeals are:

• Wyoming Statute § 42-4-101 — authorizes the Wyoming Medicaid program and delegates rulemaking authority to the Wyoming Department of Health.
• Wyoming Statute § 42-4-103 — covered services. The federal Social Security Act § 1927(d)(2)(A) permits state Medicaid programs to exclude “agents when used for anorexia, weight loss, or weight gain” from coverage. The Wyoming Department of Health has exercised this federal authority by including “Anorexiant products” in the Legend Drug Exclusions (All Medicaid Plans) bucket of the Pharmacy Services Manual.
• Wyoming Medicaid Rules Chapter 4 — administrative hearings procedure. Sections 7-11 (cited verbatim above) gate the 20-business-day administrative hearing request window, the 10-business-day acceptance/rejection notification window, the 40-day hearing window from request, and the continuation-of-benefits-during-appeal guarantee.
• 048-2 Wyo. Code R. §§ 2-4 — Medicaid Services Rules pertaining to pharmacy benefits. See Cornell Law mirror at https://www.law.cornell.edu/regulations/wyoming/agency-048/subagency-0062/chapter-2/048-2-Wyo-Code-R-SSSS-2-4.

Federal regulatory floor. 42 CFR § 431.224 governs expedited fair hearings (3 working days default under § 431.244(f)(4) when the standard timeframe could jeopardize life, health, or function). 42 CFR § 431.230 governs continuation of benefits during appeal. 42 CFR § 440.230 governs medical-necessity-based authorization. These federal floors apply uniformly across all state Medicaid programs and provide a baseline beneath any state-specific Wyoming rule.

11.6 Enrollment, spend, and fiscal context — smallest-state economics

Wyoming’s Medicaid program is the smallest US state Medicaid program by state population (and possibly the smallest by enrollee count, though this is UNVERIFIED against ND, SD, MT, VT, AK comparators). The fiscal context shapes the categorical-exclusion policy choice in three distinct ways:

Enrollment math

• CMS/Medicaid.gov October 2025 snapshot: 59,714 covered by Medicaid + CHIP (via healthinsurance.org Wyoming Medicaid page).
• KFF May 2025 fact sheet: approximately 71,000.
• Variance (UNVERIFIED): the differential is approximately 11,000 enrollees, likely a function of differing point-in-time snapshots and CHIP-inclusion-or-exclusion accounting. The CMS October 2025 snapshot reflects the post-COVID-19 PHE unwinding when many states saw enrollment declines.
• State population: approximately 580,000 (smallest US state by population).
• Medicaid + CHIP penetration: approximately 10-12% of the state population is enrolled (vs. national average of approximately 22% for non-expansion states).

Spend context

• Real Chemistry December 2024 analysis projected Wyoming’s marginal cost of adding GLP-1 obesity coverage at “less than $5 million annually” — an order of magnitude below the marginal cost in larger-population states.
• Per-capita Medicaid spending: below the national average per the KFF May 2025 fact sheet (UNVERIFIED specific dollar figure).
• Federal match: Wyoming’s standard FMAP (Federal Medical Assistance Percentage) for FY2026 is approximately 53% federal, 47% state — below the national average because Wyoming’s per-capita income is relatively high (driven by energy-sector taxes).
• Energy-economy fiscal posture: Wyoming’s General Fund is heavily dependent on oil/gas-extraction taxes (severance tax + ad valorem). The Wyoming Legacy Fund (a permanent fund similar to Alaska’s Permanent Fund Dividend, capitalized from mineral revenues) is approximately $10 billion. The fiscal capacity to fund AOM coverage exists; the political choice has been to decline.

Non-expansion fiscal math

Wyoming is one of 10 non-expansion states. The 2026 session budget amendments by Sen. Cale Case (R-Lander) were defeated 7-23 (February 19, 2026) and 5-26 (February 22, 2026). Had Wyoming expanded Medicaid:

• Approximately 23,000-40,000 additional adults under 138% FPL would have qualified for Medicaid coverage (UNVERIFIED enrollment estimate against the WyoFile / Sen. Cale Case modeling).
• The 90% federal match for expansion population would have applied (vs. the ~53% standard FMAP), reducing the marginal state cost per expansion enrollee.
• The expansion-population pharmacy benefit would have followed the same state PDL, meaning the categorical “Anorexiant products” exclusion would have applied equally to expansion-population beneficiaries.
• The marginal cost of adding AOM coverage to a larger expansion-inclusive enrollee base would have been higher than the Real Chemistry “less than $5 million annually” projection (which presumably reflects the current categorical-population enrollee base).

The non-expansion posture means a Wyoming adult under 138% FPL without dependent children and without disability typically falls in the coverage gap (above Medicaid eligibility, below ACA-marketplace subsidy thresholds). For such an adult with morbid obesity, GLP-1 access is functionally constrained to manufacturer cash-pay (NovoCare Wegovy / LillyDirect Zepbound / LillyDirect Foundayo) or compounded telehealth, with no insurance pathway available.

11.7 OptumRx ecosystem context — multi-state pharmacy-benefit administration pattern

OptumRx (UnitedHealth Group subsidiary) is a recurring pharmacy-benefit administrator across multiple state Medicaid programs in the 50-state series. Wyoming’s April 15, 2026 migration consolidates pharmacy claims and PAs onto the same OptumRx infrastructure used by South Dakota Medicaid (Pattern #45, OptumRx pharmacy claims processor since November 13, 2017) and by various MCO contracts in Vermont (Pattern #41), New Jersey, and others.

Implications of OptumRx multi-state consolidation for Wyoming providers:

• Form consistency. Providers practicing in both Wyoming and South Dakota (e.g., border-county practices in Belle Fourche, Sundance, Hot Springs, Newcastle, or in the Wind River Reservation area near the Pine Ridge Reservation) may be familiar with the OptumRx form layouts and clinical-criteria-review workflow from SD Medicaid PA submissions.
• Form differences. Despite the shared OptumRx platform, each state’s PA forms reflect that state’s specific PDL criteria. The Wyoming Miscellaneous PA Form and Brand Name PA Form are NOT identical to the SD GLP-1 Agonists PA Form (footer ID GLP1Agonists_SouthDakotaMedicaid_2026May). Wyoming has no SD-equivalent dedicated GLP-1 PA form because the WY categorical exclusion means no dedicated AOM PA form exists.
• Call center separation. Wyoming-specific OptumRx PA support lines (1-877-207-1126 for PA/Appeals/Clinical, 1-877-209-1264 for Pharmacy Help Desk) are SEPARATE from the SD-specific OptumRx lines (1-855-401-4262 urgent, 1-844-403-1029 non-urgent fax). Wyoming providers should not route Wyoming PAs through the SD lines or vice versa.
• Indication checkbox model. The SD GLP-1 PA form’s T2D-only diagnosis-checkbox pre-coding (with “Other diagnosis” freeform line) is NOT mirrored on the Wyoming PA forms because Wyoming has no dedicated GLP-1 PA form. WY uses the Miscellaneous PA Form or Brand Name PA Form, with the indication-specific clinical documentation attached as free-form narrative.

The CMS BALANCE Model and OptumRx. OptumRx has signed up to participate as a pharmacy-benefit-manager partner in various CMS BALANCE Model demonstrations across state Medicaid programs (UNVERIFIED participation in Wyoming’s arrangement). The BALANCE Model is the CMS Innovation Center demonstration aimed at improving population-health outcomes through coordinated-care delivery, including chronic-disease-management interventions that may include AOM coverage. Wyoming’s participation in BALANCE or other CMS-Innovation Center demonstrations is UNVERIFIED.

12. Pattern #47 comparisons to RI / VT / KS / ND / SD / MT

12.1 WY vs. North Dakota (Pattern #44) — closest Plains-state peer

Both states are categorical-AOM-exclusion-with-FDA-label-carve-ins states. Three key differences:

• Architecture: WY is FFS-only with no MCO at all; ND is FFS-dominant for traditional Medicaid + BCBSND-only for Medicaid Expansion under a 1915(b) waiver. WY uses WYhealth CME for care management; ND uses Acentra Health as PBM.
• Wegovy CV criteria: WY uses verbatim FDA SELECT label (BMI ≥ 27 + prior MI/stroke/PAD); ND adds an off-label Ozempic 2 mg step-through requirement that WY does not impose, plus an age 55-74 bracket, plus an A1c-normal-off-Rx T2D-negativity requirement, plus a lipid + antiplatelet concurrent therapy requirement, plus a tobacco-cessation-counseling-within-12-months requirement for tobacco users. ND’s Wegovy CV criteria are materially more restrictive.
• Zepbound OSA criteria: WY requires only sleep study within prior 12 months + obesity + 5% weight loss at 6 months; ND requires 6-month CPAP failure + 6-month comprehensive weight-management program with semaglutide + 10% weight loss at 12 months. ND’s Zepbound OSA criteria are materially more restrictive.
• Legislative posture: ND rejected Medicaid AOM coverage 12-81 (HB 1451) and 11-82 (HB 1452) on the same day in February 2025 — the most decisive legislative no-vote in the series. WY had no AOM legislation at all in 2024-2026.

12.2 WY vs. Montana (Pattern #46) — closest contiguous-state peer

Both states have categorical exclusion language and both are Mountain-West states. Three key differences:

• Exclusion language: WY uses “Anorexiant products” in the WDH Pharmacy Services Manual Legend Drug Exclusions bucket; MT uses “weight-loss medications” in the DPHHS Pharmacy Program Not Covered bucket and “The program explicitly does not reimburse for drugs prescribed for weight reduction” in the Prescription Drug Program Manual.
• Carve-in implementation: WY has three concretely-codified carve-ins (Wegovy CV, Wegovy MASH, Zepbound OSA) on the April 15, 2026 PDL; MT’s carve-out PA criteria PDFs (mpqhf.org/download/25789/ for Wegovy and mpqhf.org/download/26184/ for Zepbound) are UNVERIFIED pending direct download.
• Architecture: WY uses FFS + OptumRx + WYhealth CME; MT uses PCCM (Passport to Health since 1993) + Mountain-Pacific Quality Health (MPQH, a non-profit QIO not a commercial PBM) for PA processing.
• Expansion: MT made expansion permanent via HB 245 (signed March 27, 2025); WY remains non-expansion (defeated 7-23 / 5-26 in 2026 session).

12.3 WY vs. South Dakota (Pattern #45) — sister Dakotan / Mountain-West peer

Both states are FFS-architecture with OptumRx as pharmacy claims processor. Three key differences:

• Exclusion architecture: WY codifies the exclusion explicitly (“Anorexiant products” in the Pharmacy Services Manual); SD operates a functional exclusion by ABSENCE (no codified categorical sentence in the SD Pharmacy Services Manual; the OptumRx SD GLP-1 PA form pre-codes T2D as the only diagnosis checkbox with no obesity pathway).
• Carve-ins: WY has three concretely-codified FDA-label carve-ins (Wegovy CV, Wegovy MASH, Zepbound OSA); SD has NO codified carve-ins.
• Expansion: SD expanded Medicaid via 2022 ballot initiative (Constitutional Amendment D, effective July 1, 2023) and has HJR 5001 referring Constitutional Amendment I to the November 3, 2026 ballot (90% FMAP trigger); WY remains non-expansion.

12.4 WY vs. Vermont (Pattern #41) — categorical peer with VT’s three FDA-label carve-ins

VT and WY both maintain categorical AOM exclusions with operationalized FDA-label carve-outs. Three key differences:

• Carve-in scope: VT covers Wegovy MACE + Wegovy MASH + Zepbound OSA (same three indications as WY).
• Zepbound OSA criteria comparison: VT requires CPAP prescribed (lowest CPAP-prerequisite bar in the series); WY requires only a sleep study within the prior 12 months. WY’s OSA criteria are also less restrictive than VT’s on the reauthorization weight-loss threshold (WY 5% at 6 months; VT 5% at 6 months — comparable).
• Architecture: VT is FFS-only with no MCO + Optum-administered pharmacy benefit; WY is FFS-only with no MCO + OptumRx-administered pharmacy benefit (same OptumRx family). Both states use the same PBM family.

12.5 WY vs. Kansas (Pattern #43) — non-expansion / inverse-trajectory comparison

KS and WY are both non-expansion states (until WY decides otherwise). KS LOOSENED AOM criteria in 2024-2025 by de-listing Wegovy + Zepbound from Table 4 (BMI ≥ 40 severe-obesity gate eliminated); WY maintained the categorical exclusion with no legislative AOM activity. KS uses three-MCO architecture under a unified KDHE PDL; WY uses FFS + OptumRx + WYhealth CME.

12.6 WY vs. Rhode Island (Pattern #40) — inverse coverage trajectory

RI currently covers baseline AOM (Wegovy, Zepbound, Saxenda, Contrave for obesity) but faces a governor-proposed October 1, 2026 sunset; WY excludes baseline AOM categorically and has no legislative activity to change the posture. Where RI patients ask “will my existing coverage survive the legislature?”, WY patients ask “do I qualify for one of the three FDA-label carve-ins?”

12.7 At-a-glance comparison matrix — WY / ND / SD / MT / VT carve-in restrictiveness

Reading the matrix: Wyoming has the LEAST restrictive Zepbound OSA carve-in in the categorical-exclusion cohort (no CPAP prerequisite, no comprehensive weight-management program prerequisite, 5% weight-loss reauthorization at 6 months) and the most direct FDA-SELECT-verbatim adoption of the Wegovy CV criteria (no off-label Ozempic 2 mg step-through, no age bracket, no T2D-negativity requirement, no lipid + antiplatelet concurrent therapy requirement, no tobacco-cessation requirement). Wyoming’s carve-ins are the most patient-friendly of the categorical-exclusion-with-carve-ins cohort, even though Wyoming’s underlying categorical exclusion (“Anorexiant products”) is uncompromising for standalone obesity.

12.8 Denial-recovery playbook — the three-step decision tree

For Wyoming Medicaid beneficiaries receiving a denial on a GLP-1 carve-in PA, the operational decision tree is:

Step 1 (immediate, within 1 business day of denial receipt): Diagnose the denial reason

• Call the OptumRx PA/Appeals/Clinical Call Center at 1-877-207-1126.
• Ask the agent to read the denial rationale aloud and to identify the specific clinical-criteria element that was not met.
• Categorize the denial into one of four buckets:
  • Documentation deficiency — missing BMI documentation, missing sleep study, missing fibrosis stage documentation, missing ICD-10 diagnosis code, missing consult note.
  • Clinical-criteria mismatch — documented BMI 26.5 vs. required ≥ 27 for Wegovy CV; AHI 14 vs. required > 15 for Zepbound OSA; F1 fibrosis vs. expected F2-F3 for Wegovy MASH (per practical expectation).
  • Indication non-match — PA submitted for obesity indication only (Wegovy/Zepbound for chronic-weight-management is categorically excluded).
  • System / migration issue — April 15, 2026 OptumRx migration created form-version mismatches or PA re-certification gaps; resubmission on the current form should resolve.

Step 2 (within 20 business days of denial notice receipt): File reconsideration

• Documentation deficiency: gather the missing documentation, draft a clarification cover letter, and re-fax to OptumRx PA Department at 1-866-964-3472. Reference the original PA reference number.
• Clinical-criteria mismatch: if the patient barely missed a threshold (BMI 26.5, AHI 14), evaluate whether a re-measurement or a stricter prior-12-month criterion lookup yields a qualifying datapoint. If the criterion cannot be met, redirect to a different pathway (e.g., Zepbound OSA cannot be met but Wegovy CV can, if the patient has cardiovascular disease).
• Indication non-match: re-evaluate whether the patient qualifies under one of the three FDA-label carve-ins. A patient submitted for “obesity” will be denied; the same patient with documented cardiovascular disease can be re-submitted under the Wegovy CV pathway.
• System / migration issue: download the current PA form from https://www.wymedicaid.org/pa-pdl/pa-forms-related-info.html and re-submit.

Step 3 (within 20 business days of adverse-action notice mailing): File administrative hearing

• If reconsideration fails, file the administrative hearing request to WDH via email, phone, certified mail, or in-person delivery within 20 business days of the mailing of the adverse-action notice.
• The WDH has 10 business days from receipt to notify acceptance/rejection in writing.
• Hearing must be held within 40 days of the request unless otherwise provided by law or by the parties’ agreement, or if a contestant requests a continuance.
• Continuation of benefits during appeal is guaranteed if the hearing request is filed before the effective date of the adverse action.
• Hearing forum: Wyoming Office of Administrative Hearings (OAH), 1800 Carey Ave., 5th Floor, Cheyenne, WY 82002 | (307) 777-6660 | Fax (307) 777-5269.

Practical tactical considerations:

• Engage the prescriber as the appeal lead. A Wyoming Medicaid beneficiary may request reconsideration or a hearing themselves, but the prescriber (cardiologist, hepatologist, sleep medicine specialist) is the most effective driver of the clinical narrative.
• Use specialist letterhead. An appeal supported by a cardiology specialist’s detailed clinical narrative carries more weight than a primary-care attestation alone, particularly for the Wegovy CV pathway.
• Cite the FDA label verbatim. For the Wegovy CV pathway, citing the FDA SELECT supplement (March 8, 2024 approval) and quoting the trial population characteristics provides external validation for the BMI ≥ 27 + cardiovascular disease criterion.
• Anticipate the “obesity” mis-coding pitfall. The most common Wyoming denial pattern is when the PA submission lists E66 (overweight/obesity) as the primary ICD-10 diagnosis. Re-submit with the CV ICD-10 (I21.x / I25.2 / I63.x / I70.2x / I73.9) as primary and the obesity code as secondary — this aligns with the FDA SELECT label, which approves Wegovy for the CV indication in patients with established cardiovascular disease AND obesity or overweight (not for obesity alone).

12.9 Cash-pay and self-pay deep dive for Wyoming patients

Wyoming Medicaid beneficiaries who do not qualify for any of the three carve-ins (Wegovy CV, Wegovy MASH, Zepbound OSA) face a categorical coverage gap for the standalone obesity indication. The cash-pay landscape as of May 15, 2026 includes:

NovoCare Wegovy cash-pay (verified May 15, 2026)

• Standard pen formats (0.25 / 0.5 / 1.0 / 1.7 / 2.4 mg): $199-$349/month tiered by titration step.
• High-dose pen: $399/month.
• Oral semaglutide tablets: $149/month.
• The $499 baseline NovoCare price retired in May 2026.
• Eligibility: cash-pay through NovoCare requires a valid prescription and no insurance billing.
• Pharmacy delivery: NovoCare ships directly to the patient or to a participating Wyoming pharmacy.

LillyDirect Zepbound vials cash-pay

• Vial formats (2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg): $299-$699/month tiered by dose strength.
• Vial delivery to a participating Wyoming pharmacy or direct-to-patient.
• Eligibility: cash-pay through LillyDirect requires a valid Zepbound prescription and no insurance billing.

LillyDirect Foundayo (orforglipron) self-pay

• FDA-approved April 1, 2026 for chronic weight management in adults with obesity or overweight with comorbidity.
• Self-pay price: $149/month.
• Oral GLP-1 receptor agonist (small molecule, not a peptide) — no injection required.
• Eligibility: cash-pay through LillyDirect; eligibility for the $149 price requires no insurance billing.

Patient assistance programs

• Novo Nordisk Patient Assistance Program (PAP) for Wegovy / Saxenda / Ozempic / Victoza / Rybelsus — income-tested support.
• Lilly Cares Foundation for Zepbound / Mounjaro / Trulicity — income-tested support.
• Application via the manufacturer’s PAP portal; income documentation required.

LegitScript-approved compounded telehealth (with caveats)

• Compounded semaglutide: typical market price $99-$199/month (May 2026).
• Compounded tirzepatide: typical market price $149-$249/month.
• FDA compounding-resolved status caveats: the FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025. New compounded prescriptions written after the resolution dates require documented patient-specific clinical need beyond shortage justification (e.g., dose-specific clinical need for a strength or dosage form not available in commercially-marketed product). Patients on long-running compounded semaglutide / tirzepatide regimens may have been transitioned to brand product or to a different compounded formulation post-resolution.
• LegitScript verification: Wyoming patients seeking compounded telehealth should verify the prescriber and pharmacy through LegitScript’s Healthcare Merchant Certification database (https://www.legitscript.com/services/certification/healthcare-merchant-certification/) to ensure compliance with state pharmacy-board regulations and to avoid counterfeit-medication risk.

State-employee EGI plan (CVS Caremark, effective January 1, 2026)

Wyoming patients who transition to a state-employee position (e.g., taking a job with the Wyoming Department of Health, the University of Wyoming, the Wyoming Department of Transportation, a county or municipal government, or another state-employee-eligible employer) gain access to the EGI plan’s GLP-1 weight management coverage through CVS Caremark. This is the same inverse-coverage-posture seen in ND Pattern #44 (where the 2025 commercial EHB Benchmark Plan covers GLP-1s for morbid obesity but Medicaid does not). The EGI plan’s specific prior authorization criteria, BMI thresholds, and reauthorization requirements are UNVERIFIED in publicly available WY A&I documentation as of May 15, 2026 — patients considering a state-employee transition should request a copy of the EGI formulary and PA criteria from Wyoming A&I Human Resources.

13. UNVERIFIED items honestly flagged

The following items could not be directly verified from publicly available Wyoming Medicaid primary sources as of May 15, 2026 and should be confirmed before relying on them for individual clinical or coverage decisions:

1. KFF May 2025 enrollment (71K) vs. CMS October 2025 (59,714) variance. The differing point-in-time snapshots and CHIP-inclusion-or-exclusion accounting are the likely drivers, but the operational enrollment for pharmacy-benefit planning purposes is UNVERIFIED.
2. “Obese adult” numeric BMI threshold in the Zepbound OSA criteria. The PDL line says “obese adults” without specifying a numeric BMI threshold. The FDA Zepbound label baseline of BMI ≥ 30 kg/m² is the most likely applicable threshold but is not explicitly stated.
3. EPSDT pediatric AOM override. Whether Wyoming Medicaid honors EPSDT-based medical-necessity claims for adolescent Wegovy obesity-indication coverage is UNVERIFIED in publicly available WDH documentation. The federal EPSDT mandate at 42 U.S.C. § 1396d(r) is the regulatory anchor.
4. WY participation in CMS BALANCE Model. Whether Wyoming has signed up for the CMS BALANCE (Building Better Health Outcomes through Aligned Networks and Coordinated Engagement) Model or other CMS-Innovation Center demonstrations relevant to obesity-care delivery is UNVERIFIED.
5. Wegovy MASH PDL/ATC inconsistency. The PDL line declares Wegovy MASH-approved but the ATC chart redirected to only lists cardiovascular-disease criteria. The operational MASH PA review criteria are UNVERIFIED.
6. Smallest-Medicaid-enrollment-state ranking claim. Wyoming may or may not be the smallest US state Medicaid program by enrollee count — the CMS October 2025 snapshot would need to be compared against North Dakota, South Dakota, Montana, Vermont, Alaska, and other low-population-state snapshots to confirm the ranking. The smallest-by-population claim is concretely supported.
7. Imcivree (setmelanotide) PDL position. Whether WY Medicaid covers Imcivree for confirmed POMC / PCSK1 / LEPR deficiency or Bardet-Biedl syndrome (as ND Pattern #44 does explicitly) is UNVERIFIED in publicly available WY Medicaid documentation.
8. Component coverage for Contrave / Qsymia / phentermine / phendimetrazine / diethylpropion. Whether the WY Medicaid PDL covers the individual components of branded fixed-combination AOMs (bupropion, naltrexone separately) for non-AOM indications (smoking cessation for bupropion, opioid use disorder for naltrexone) is UNVERIFIED in this context.
9. WY-specific expedited fair-hearing deadline. The federal floor under 42 CFR § 431.224 is 3 working days; WY-specific deadline is UNVERIFIED in publicly available WDH documentation.

14. What Wyoming Medicaid beneficiaries should do right now

If you have established cardiovascular disease (prior MI, prior stroke, OR peripheral artery disease) AND have BMI ≥ 27: you qualify for the Wegovy CV/SELECT carve-in. Ask your prescriber to submit a PA via the Miscellaneous PA Form or Brand Name PA Form to OptumRx fax 1-866-964-3472 with ICD-10 diagnosis code (I21.x / I25.2 / I63.x / I70.2x / I73.9) + BMI documentation + cardiology/vascular/neurology consult note. Adjudication is within 24-72 hours per the Pharmacy Services Manual page 22 verbatim.

If you have biopsy-proven or non-invasive-test-confirmed MASH: you may qualify for the Wegovy MASH carve-in. Engage a hepatology, gastroenterology, or endocrinology consultant. Document fibrosis stage (FibroScan/VCTE, MR-PDFF, MRE, ELF score). Submit PA with ICD-10 K75.81 + consult note + fibrosis documentation. Note the PDL/ATC inconsistency — call OptumRx PA/Appeals/Clinical Call Center at 1-877-207-1126 before submission to confirm operational PA review criteria.

If you have moderate-to-severe OSA (AHI > 15 by sleep study within prior 12 months) AND are an obese adult: you qualify for the Zepbound OSA carve-in. This is among the LEAST restrictive OSA carve-ins in the 50-state series — Wyoming does NOT require CPAP failure or a comprehensive weight-management program prerequisite. Submit PA with ICD-10 G47.33 + sleep study documentation + BMI documentation. Implied 6-month initial approval window; reauthorization at 6 months requires ≥ 5% weight loss; reauthorization at 12 months requires documented OSA improvement.

If you have T2D and ASCVD (or ASCVD risk factors): the metformin trial is WAIVED per the PDL verbatim. You qualify directly for a preferred GLP-1 (exenatide, Rybelsus, Trulicity, or brand Victoza). For brand Ozempic or Mounjaro, you need to fail a preferred GLP-1 for 90 days first — or qualify via the Wegovy CV carve-in if you also have SELECT-eligible cardiovascular disease.

If you have T2D without ASCVD or risk factors: trial metformin for ≥ 90 days as a documented step before requesting a preferred GLP-1.

If you have obesity without one of the three carve-in qualifying indications (CV, MASH, OSA): Wyoming Medicaid does NOT cover GLP-1s for the standalone obesity indication. Practical paths are (1) NovoCare Wegovy cash-pay ($199-$349/month standard pens; $399/month HD pen; $149/month oral semaglutide tablets per May 15, 2026 NovoCare verification); (2) LillyDirect Zepbound vials at $299-$699/month; (3) LillyDirect Foundayo (orforglipron, FDA-approved April 1, 2026) at $149/month self-pay; (4) patient assistance programs (Novo Nordisk PAP, Lilly Cares) for income-tested support; (5) LegitScript-approved compounded telehealth at $99-$199/month for semaglutide and $149-$249/month for tirzepatide (with the FDA compounding-resolved caveat for both molecules); (6) if you transition to a Wyoming state-employee position, the EGI plan launched GLP-1 weight management coverage through CVS Caremark effective January 1, 2026 — state-employee coverage is more generous than Medicaid coverage on the obesity indication.

If your PA is denied: do not give up after the first denial. Step 1: file a reconsideration request within 20 business days of the receipt of the notice of denial. Submit to OptumRx PA Department, PO Box 21719, Cheyenne, WY 82003 | Fax 1-866-964-3472. Call OptumRx PA/Appeals/Clinical Call Center at 1-877-207-1126 to verify denial rationale before re-submission. Step 2: if reconsideration fails, file an administrative hearing request within 20 business days of the mailing of the notice of adverse action. Submit electronically by email to WDH, verbally, by certified mail return receipt requested, or in person. WDH has 10 business days to accept or reject; hearing within 40 days of request. The Wyoming OAH is at 1800 Carey Ave., 5th Floor, Cheyenne, WY 82002 | (307) 777-6660. Continuation of benefits is automatic if you file the hearing request before the effective date of the adverse action.

Related coverage

• Montana Medicaid GLP-1 Coverage (Pattern #46) — closest contiguous Mountain-West peer: also categorical exclusion language (“weight-loss medications” in DPHHS Pharmacy Program Not Covered bucket); MT uses PCCM (Passport to Health since 1993) + Mountain-Pacific Quality Health (MPQH) for PA processing vs. WY’s FFS + OptumRx + WYhealth CME; MT made expansion permanent via HB 245 (signed March 27, 2025) while WY remains non-expansion (defeated 7-23 / 5-26 in 2026 session); SB 417 (MT AOM mandate) died 11-1 in committee March 1, 2025 while WY had no AOM legislation
• South Dakota Medicaid GLP-1 Coverage (Pattern #45) — sister Dakotan peer also under OptumRx pharmacy claims processing; SD operates a functional AOM exclusion by ABSENCE (no codified categorical sentence in the SD Pharmacy Services Manual; the OptumRx SD GLP-1 PA form pre-codes T2D as the only diagnosis checkbox) while WY codifies the exclusion explicitly (“Anorexiant products” in the WDH Pharmacy Services Manual page 8); SD has NO codified carve-ins while WY has three (Wegovy CV, Wegovy MASH, Zepbound OSA); SD expanded Medicaid via 2022 ballot initiative (Amendment D) and has HJR 5001 referring Constitutional Amendment I (90% FMAP trigger) to the Nov 3, 2026 ballot; WY remains non-expansion
• North Dakota Medicaid GLP-1 Coverage (Pattern #44) — closest categorical-AOM-exclusion-with-FDA-label-carve-ins peer in the 50-state series: ND covers Wegovy MACE + Wegovy MASH + Zepbound OSA + Ozempic/Victoza no-PA for antipsychotic-induced weight gain + Imcivree + low-cost AOMs without PA but NOT Wegovy/Zepbound/Saxenda for standalone obesity; ND is materially more restrictive than WY on both Wegovy CV (off-label Ozempic 2 mg step-through + age 55-74 bracket + tobacco cessation requirement) and Zepbound OSA (6-month CPAP failure + 6-month semaglutide comprehensive weight-management program + 10% weight-loss reauthorization); ND HB 1451 / HB 1452 FAILED 12-81 / 11-82 on House floor 02/12/2025 (most decisive legislative no-vote in series) vs. WY no AOM legislation at all in 2024-2026
• Kansas Medicaid GLP-1 Coverage (Pattern #43) — inverse trajectory non-expansion peer: KS covers Wegovy + Zepbound for standalone obesity (at adult BMI ≥ 30 or ≥ 27 with comorbidity) and LOOSENED criteria 2024-2025 by de-listing both drugs from Table 4 (BMI ≥ 40 severe-obesity gate eliminated); KS uses three-MCO architecture under unified KDHE PDL vs. WY’s FFS + OptumRx + WYhealth CME
• Vermont Medicaid GLP-1 Coverage (Pattern #41) — closest categorical-FDA-carve-in peer: VT excludes baseline AOM but operationalizes Wegovy MACE + Wegovy MASH + Zepbound OSA (same three indications as WY); VT’s Zepbound OSA criteria require CPAP prescribed (lowest CPAP-prerequisite bar in the series) while WY requires no CPAP prerequisite at all; FFS-only architecture in both states, both using Optum-family PBM (Optum for VT, OptumRx for WY)
• Rhode Island Medicaid GLP-1 Coverage (Pattern #40) — inverse coverage trajectory: RI currently covers Wegovy + Zepbound + Saxenda + Contrave for obesity but faces a governor-proposed October 1, 2026 sunset; WY excludes baseline AOM categorically and has no legislative activity to change the posture
• Maine MaineCare GLP-1 Coverage (Pattern #39) — categorical exclusion with NO Wegovy MASH carve-out; LD 480 killed March 20, 2025
• Nebraska Medicaid GLP-1 Coverage (Pattern #38) — categorical exclusion with 45-74 age gate + 6-month MASH prerequisite; LB907 Indefinitely Postponed
• Utah Medicaid GLP-1 Coverage (Pattern #37) — 6/30/2026 sunset of in-lab attended PSG carve-out
• West Virginia Medicaid GLP-1 Coverage (Pattern #36) — categorical exclusion with Wegovy CV + Zepbound OSA + Wegovy MASH carve-outs via WVU RDTP
• Mississippi Medicaid GLP-1 Coverage (Pattern #35) — only non-expansion southern positive-coverage state; SPA 23-0013 carve-back-in with pediatric ages 12+ pathway
• 50-state Medicaid GLP-1 coverage map — full series overview with pattern taxonomy
• GLP-1 insurance coverage hub — Medicare, Medicaid, and commercial coverage landscape
• GLP-1 insurance dropped coverage appeal playbook — denial-recovery patterns applicable across states

Primary sources

1. Wyoming Medicaid Preferred Drug List (effective April 15, 2026)
2. Wyoming Medicaid Additional Therapeutic Criteria Chart (effective April 15, 2026)
3. Wyoming Medicaid Dosage Limitation Chart (effective April 15, 2026)
4. Wyoming Medicaid Pharmacy Services Manual Revision 27 (effective April 15, 2026)
5. Wyoming Medicaid Prior Authorization Forms hub
6. Wyoming Medicaid main portal (wymedicaid.org)
7. Wyoming Department of Health — Medicaid landing
8. Wyoming Medicaid Pharmacy Services landing
9. Wyoming Medicaid Rules Chapter 4 (administrative hearings)
10. 048-2 Wyo. Code R. §§ 2-4 (Cornell Law)
11. Wyoming Office of Administrative Hearings (OAH)
12. KFF — Medicaid Coverage of and Spending on GLP-1s (January 16, 2026)
13. 42 CFR Part 431 Subpart E (federal Medicaid fair-hearing standards)
14. healthinsurance.org — Wyoming Medicaid eligibility and enrollment
15. KFF Wyoming Medicaid Fact Sheet (May 2025)
16. Wyoming Medicaid Monthly Snapshot (December 2024)
17. WyoFile — Medicaid expansion analysis
18. Wyoming Public Media — Medicaid bills (February 13, 2026)
19. Wyoming News — WY in minority of states where Medicaid doesn’t cover GLP-1s
20. Wyoming A&I — Weight Management & GLP-1 (state-employee EGI plan, effective January 1, 2026)
21. Real Chemistry — state-by-state analysis of Medicaid coverage for GLP-1 weight loss